Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma1

By Cooper Ljn   Ausubel L   Gutierrez M   Stephan S   Shakeley R   Olivares S   Serrano Lm   Burton L   Jensen McV   Forman Sj   Digiusto Dl  

Cytotherapy, Vol. 8, Iss. 2, 2006-05 ,pp. : 105-117

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes

By Watanabe N   Kamachi Y   Koyama N   Hama A   Liang J   Nakamura Y   Yamamoto T   Isomura M   Kudo K   Kuzushima K   Kojima S  

Cytotherapy, Vol. 6, Iss. 5, 2004-10 ,pp. : 514-522

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy

By Jensen Mc   Cooper Ljn   Wu Am   Forman Sj   Raubitschek A  

Cytotherapy, Vol. 5, Iss. 2, 2003-01 ,pp. : 131-138

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function

By Robinet E   Fehse B   Ebeling S   Sauce D   Ferrand C   Tiberghien P  

Cytotherapy, Vol. 7, Iss. 2, 2005-05 ,pp. : 150-157

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation

By Ciceri F   Bonini C   Gallo-Stampino C   Bordignon C  

Cytotherapy, Vol. 7, Iss. 2, 2005-05 ,pp. : 144-149

Ashgate Publishing Ltd

Access to resources Recommend Favorite